Pal et al. screened for parkin, LRRK2 and GBA mutations in young onset PD patients, including 99 receiving DBS treatment and 684 without DBS.21 When analyzed together, mutation carriers were significantly more common in the DBS group compared to the non-DBS group (26.5% vs. 16,8%). This evidence concerns the gene LRRK2 and Parkinson disease.